Masimo Corporation

NASDAQ:MASI

Medical - Devices

Healthcare
$179.95 +0.00%

+$0.00 today

Market cap
$9.42B
Beta
1.10
P/E (TTM)
123.1
EPS (TTM)
$1.46
52W Low $125.94High $179.99

Volume 0.00M

Average 1.08M

MASI EBITDA Margin

EBITDA as a percentage of revenue.

Masimo CorporationNASDAQ: MASI

EBITDA Margin · Q1 FY2026 · quarter ended Apr 2026

EBITDA Margin narrows to 21.2%

EBITDA Margin was 21.2% in Q1 FY2026, down 1.9 pp from a year earlier. On a trailing-twelve-month basis it was 22.1%, up 28.1 pp year over year. Over 3 fiscal years it widened by 5.1 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 2 analysts of 13.8% for the fiscal year ending Jan 2027, down from 22.6% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterApr 2026
21.2%-1.9 pp QoQ
Last fiscal yearJan 2026
22.6%+30.1 pp YoY
LTMApr 2026
22.1%+28.1 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1.9 pp-5.6 pp-3.7 pp
1 year+30.1 pp-8.8 pp-38.9 pp
3 years+5.1 pp-8.8 pp-13.9 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
22.6%
Year-over-year change
+30.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How MASI compares with its peers on the latest reported figures

  • MASI's LTM Apr 2026 EBITDA Margin of 22.1% is the 3rd highest of the 10 companies compared; the peer median is 7.7%.
  • Its year-over-year change of +28.1 pp is the 2nd highest of 10, against a peer median of -2.7 pp.
  • Over three fiscal years its change of +5.1 pp compares with a peer median of -0.1 pp.
MASI Competitors Peer median
EBITDA Margin for MASI and competitors
Company Period LTM level YoY 3-year change
STVNStevanato Group S.p.A.LTM Jun 202624.3% -2.8 pp-0.4 pp
RGENRepligen CorporationLTM Jun 202622.3% +5.6 pp-9.9 pp
MASIMasimo CorporationLTM Apr 202622.1% +28.1 pp+5.1 pp
ATRAptarGroup, Inc.LTM Jun 202620.9% -1.5 pp+3.7 pp
BIOBio-Rad Laboratories, Inc.LTM Jun 202619.9% -6.2 pp+208.5 pp
HSICHenry Schein, Inc.LTM Jun 20267.7% +0.2 pp-0.1 pp
BAXBaxter International Inc.LTM Jun 20266.5% -3.0 pp+24.3 pp
AVTRAvantor, Inc.LTM Jun 20261.9% -19.3 pp-18.1 pp
MOHMolina Healthcare, Inc.LTM Sep 20260.8% -2.7 pp-2.1 pp
RYTMRhythm Pharmaceuticals, Inc.LTM Sep 2026-61.7% +35.2 pp+645.4 pp
ABVXAbivax S.A.FY2025— ——
Peer median (excluding MASI) 7.7%-2.7 pp-0.1 pp

Competitors are the stored peer set for MASI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Jan 2026
Revenue1.24B2.04B2.05B2.09B1.53B
Cost of Revenue430.8M977M1.04B1.09B581.7M
Gross Profit808.4M1.06B1B1B945.2M
Gross Margin65.2%52.0%49.0%48.0%61.9%
Research & Development137.2M191.4M175.2M222.8M126.4M
Selling, General & Admin395.4M657.4M664M743.8M506M
Operating Expenses532.6M848.8M867M1.27B632.4M
Depreciation & Amortization35.6M136.1M98.3M103M38.8M
EBITDA310.3M355.2M236.7M(158.7M)344.6M
EBITDA Margin25.0%17.4%11.6%-7.6%22.6%
Operating Income275.8M210M136.5M(266.7M)312.8M
Operating Margin22.3%10.3%6.7%-12.7%20.5%
Interest Income900K1.8M3M4.8M3.4M
Interest Expense300K25.7M50.3M43.6M33.2M
Other Income / Expenses(1.4M)(16.6M)(48.4M)(38.6M)(40.2M)
Income Before Tax274.4M193.4M88.1M(305.3M)272.6M
Pre-Tax Margin22.1%9.5%4.3%-14.6%17.9%
Income Tax Expense44.8M49.9M6.6M(400K)64.9M
Net Income229.6M143.5M81.5M(304.9M)(151.5M)
Net Margin18.5%7.0%4.0%-14.6%-9.9%
EPS (Basic)4.162.681.54(5.72)(2.83)
EPS (Diluted)3.982.601.51(5.72)(2.80)
Weighted Avg Shares55.17M53.6M52.8M53.3M53.6M
Weighted Avg Shares (Diluted)57.68M55.2M54.1M53.3M54.2M

Masimo Corporation

NASDAQ:MASI

Intrinsic Alpha fair value

Locked

Current Price

$179.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.